1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > LAMEA Oncology/Anti-cancer drugs Market - Opportunities and Forecasts, 2014 - 2021

LAMEA Oncology/Anti-cancer drugs Market - Opportunities and Forecasts, 2014 - 2021

  • February 2016
  • -
  • Allied Market Research

Summary

Table of Contents

Oncology/Anti-cancer drugs are used for treating various cancer types for improving and prolonging a patients survival time. Biological drugs, based on monoclonal antibodies (mAbs) would emerge as a preferred option for treating various cancer types, especially blood cancer (leukaemia). The rising incidence and prevalence of various cancer types, new cancer treatments and growing importance of biological and targeted drug therapies, are driving the market growth of LAMEA oncology/anti-cancer drugs. In addition, increasing demand of anti-cancer drugs for the treatment of ageing population, rising government funds and improved treatment results, are major factors boosting the market growth. However, the high cost involved in new drug development, coupled with threat of failure and adverse effects associated with anti-cancer drugs therapies, would restrain the growth of the LAMEA market. Moreover, accessibility of anti-cancer drugs incurred by high cost, is a major challenge that is expected to further impede the performance of anti-cancer drugs in LAMEA region. Nevertheless, commercialization of advanced therapeutics, such as targeted therapies and immunotherapies (biologic therapies) would reduce the negative influence of restraints and fuel the market growth.The LAMEA oncology drugs market is segmented into therapeutic modalities, cancer types and countries. Therapeutic modalities segment is further categorized into chemotherapy, targeted therapy, immunotherapy (biologic therapy), hormonal therapy and others. The LAMEA oncology drugs market is expected to reach $17,072.2 million by 2021. Patent expiration of key anti-cancer drugs such as Herceptin (Patent Expiration: EU-2014; US-2019), Erbitux (Patent Expiration: EU-2014; US-2016), Rituxan (Patent Expiration: EU-2013; US-2018) and Avastin (Patent Expiration: EU-2018; US-2019), is expected to boost the growth of cancer biosimilars market by 2021. Further, the biological therapy is the fastest growing segment at a CAGR of 12.2%, throughout the analysis period, on account of high efficacy and target specific action. Moreover, blood cancer drugs market was the largest revenue generating application segment in 2015, owing to the high cost of drugs (immunotherapies), used for the treatment of blood cancer.Based on countries the LAMEA region is segmented into nine countries named Brazil, Argentina, Nigeria, South Africa, Iraq, Iran, Algeria, Saudi Arabia and Egypt. Brazil dominates the LAMEA market closely followed by Argentina, owing to rising incidence of cancer, high expenditure and gross national income (GNI) of Brazil specifically. In addition, LAMEA market is poised to grow at a promising CAGR of 8.6% during the forecast period. This high growth rate is majorly attributed to the increasing awareness towards advanced therapies, namely immunotherapies and increase in per capita healthcare spending.The key companies profiled in the report include Amgen Inc., AstraZeneca Plc., Roche Diagnostics, GlaxoSmithKline PLC, Merck & Co., Novartis AG, AbbVie Inc. Sanofi, EIMC United Pharmaceuticals (EUP) and Actavis plc.

KEY BENEFITS
:The report provides quantitative analysis of the current market and estimations through 2014-2021 that assists in identifying the prevailing market opportunities.The report helps in understanding the strategies adopted by various companies for gaining market share in the anti-cancer drugs market.The report provides a comprehensive analysis of factors that drive and restrict the growth of the LAMEA anti-cancer drugs market.Market conditions of anti-cancer drugs market across LAMEA region are comprehensively analyzed.Competitive intelligence highlights the business practices followed by leading market players across various geographies.SWOT analysis enables to study the internal environment of the leading companies for strategy formulation.LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET KEY SEGMENTS:LAMEA oncology/anti-cancer drugs market is segmented into therapeutic modalities, cancer types and countries.By Therapeutic modalitiesChemotherapyTargeted TherapyImmunotherapy (Biologic Therapy)Hormonal TherapyOthersBy Cancer TypesBlood CancerBreast CancerGastrointestinal CancerRespiratory/Lung CancerSkin CancerOther CancersBy CountriesBrazilArgentinaNigeriaSouth AfricaIraqIranAlgeriaSaudi ArabiaEgyptOther LAMEA countries

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 52400
  • Industry report
  • January 2017
  • by Venture Planning Group

This new 74-country survey from VPGMarketResearch.com is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic ...

2017 Global Cancer Diagnostics Market: New Frontiers, Business Challenges, Emerging Technologies, Competitive Landscape

2017 Global Cancer Diagnostics Market: New Frontiers, Business Challenges, Emerging Technologies, Competitive Landscape

  • $ 21100
  • Industry report
  • March 2017
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. VPGMarketResearch.com's new report is a study of the major business opportunities emerging in the global cance ...

2017 World Cancer Diagnostics Market Future Horizons and Growth Strategies: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities

2017 World Cancer Diagnostics Market Future Horizons and Growth Strategies: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 21100
  • Industry report
  • March 2017
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. VPGMarketResearch.com's new report is a seven-country strategic analysis of the major business opportunities ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.